2023-506680-34-00招募中3 期
A Phase 3, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of UGN-102 as Primary Chemoablative Therapy in Patients with Low Grade (LG) Non-Muscle-Invasive Bladder Cancer (NMIBC) at Intermediate Risk (IR) of Recurrence.
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 161
- 试验地点
- 33
- 主要终点
- CRR, defined as the proportion of patients who achieved CR at the 3 month Visit (3 months after the first instillation of UGN-102) as determined by cystoscopy, for cause biopsy, and urine cytology.
研究概览
简要总结
To evaluate the tumor ablative effect of UGN 102 in patients with LG NMIBC.
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 否
入选标准
- •Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.
- •Patient must be ≥ 18 years of age at the time of signing the ICF.
- •Patient who has LG NMIBC (Ta) histologically confirmed by cold cup biopsy at Screening or within 8 weeks before Screening.
- •History of LG NMIBC requiring treatment with TURBT. Note: This refers to a previous episode(s) and not to the current episode for which the patient is being screened.
- •Has intermediate risk disease, defined as having 1 or 2 of the following: a. Presence of multiple tumors. b. Solitary tumor > 3 cm. c. Early or frequent recurrence (≥ 1 occurrence of LG NMIBC within 1 year of the current diagnosis at the initial Screening Visit).
- •Negative voiding cytology for HG disease within 8 weeks before Screening.
- •Has adequate organ and bone marrow function as determined by routine laboratory tests as below: • Leukocytes ≥ 3,000/μL (≥ 3 × 109/L). • Absolute neutrophil count ≥ 1,500/μL (≥ 1.5 × 109/L). • Platelets ≥ 100,000/μL (≥ 100 × 109/L). • Hemoglobin ≥ 9.0 g/dL. • Total bilirubin ≤ 1.5 × upper limit of normal (ULN). • Aspartate aminotransferase (AST)/Alanine aminotransferase (ALT) ≤ 2.5 × ULN. • Alkaline phosphatase (ALP) ≤ 2.5 × ULN. • Estimated glomerular filtration rate (eGFR) ≥ 30 mL/min
- •Has an anticipated life expectancy of at least the duration of the trial.
- •Both male and female patients: Contraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. a.Female partner of male patient: Willing to use 2 acceptable forms of effective contraception from enrollment through 6 months post treatment if the female partner is of childbearing potential (defined as premenopausal women who have not been sterilized). Acceptable methods of birth control which are considered to have a low failure rate (ie, less than 1% per year) when used consistently and correctly, such as implants, injectable, combined (estrogen/progesterone) oral contraceptives, intrauterine devices (only hormonal), condoms with spermicide, sexual abstinence* or vasectomized partner. *Sexual abstinence is defined as refraining from intercourse from enrollment through 6 months post treatment. Periodic abstinence (calendar, symptothermal, post-ovulation methods) is NOT an acceptable method of contraception. b.Female patient: Willing to use 2 acceptable forms of effective contraception from enrollment through 6 months post treatment if the patient is of childbearing potential (defined as premenopausal women who have not been sterilized).
排除标准
- •Received Bacillus Calmette-Guérin (BCG) treatment for urothelial carcinoma (UC) within previous 1 year.
- •Is pregnant or breastfeeding.
- •Has an underlying substance abuse or psychiatric disorder such that, in the opinion of the Investigator, the patient would be unable to comply with the protocol.
- •History of prior treatment with an intravesical chemotherapeutic agent in the past 2 years except for a single dose of chemotherapy immediately after any previous TURBT.
- •Has participated in a study with an investigational agent or device within 30 days of enrollment.
- •Has previously participated in a study in which they received UGN-
- •Has any other active malignancy requiring treatment with systemic anticancer therapy (eg, chemotherapy, immunotherapy, radiation therapy). Superficial cancers such as cutaneous basal cell or squamous cell carcinomas that can be treated locally are allowed.
- •Has any other clinically significant medical or surgical condition that in the Investigator’s opinion could compromise patient safety or the interpretation of study results.
- •History of HG bladder cancer (papillary or carcinoma in situ [CIS]) in the past 2 years.
- •Known allergy or sensitivity to mitomycin that in the Investigator’s opinion cannot be readily managed.
- •Clinically significant urethral stricture that would preclude passage of a urethral catheter.
- •History of: a. Neurogenic bladder. b. Active urinary retention. c. Any other condition that would prohibit normal voiding.
- •Past or current muscle invasive bladder cancer (ie, T2, T3, T4) or metastatic UC.
- •Current tumor grading of T
- •Concurrent upper tract urothelial carcinoma (UTUC).
- •Evidence of active urinary tract infection (UTI) that in the Investigator’s opinion cannot be treated and resolved prior to biopsy and/or administration of study treatment.
结局指标
主要结局
CRR, defined as the proportion of patients who achieved CR at the 3 month Visit (3 months after the first instillation of UGN-102) as determined by cystoscopy, for cause biopsy, and urine cytology.
CRR, defined as the proportion of patients who achieved CR at the 3 month Visit (3 months after the first instillation of UGN-102) as determined by cystoscopy, for cause biopsy, and urine cytology.
次要结局
- 1. DOR in patients who achieved CR at the 3 month Visit, defined as the time from the date of evidence of CR at the 3 month Visit to the earliest date of recurrence or progression as determined using the date of cystoscopy, for cause biopsy, or cytology, or death due to any cause, whichever occurred first.
- 2. DCR rate at scheduled disease assessment time points, defined as the proportion of patients who achieved CR at the 3-month Visit and maintained CR (ie, no detectable disease) up to that particular follow up disease assessment.
- 3. DFS in patients who achieved CR at the 3 month Visit, defined as the time from first dose to the earliest date of recurrence or progression as determined using the date of cystoscopy, for cause biopsy, or cytology, or death due to any cause, whichever occurred first.
- 4. The safety profile of UGN-102 will be evaluated through the reporting of AEs, including SAEs and AESIs, and through standard clinical and laboratory tests (eg, hematology and chemistry, urinalysis, physical examination, and vital signs).
- Exploratory 1. TTR in patients who were NCR (residual disease) at the 3-month Visit, defined as the time from the date of first treatment after NCR to the earliest date of recurrence or progression as determined using the date of cystoscopy, for cause biopsy, or cytology, whichever occurred first.
- Exploratory 2. Number (%) of response outcomes evaluated at the first disease assessment visit after SOC.
- Exploratory 3. Proportion of patients whose planned NMIBC treatment at baseline was downgraded following treatment with UGN-102 (eg, from TURBT to biopsy and/or fulguration).
- Exploratory 4. Changes from baseline in patient scores on the QLQ C30 and QLQ-NMIBC24 questionnaires.
研究者
Sunil Raju
Scientific
Urogen Pharma Ltd.
研究点 (33)
Loading locations...
相似试验
尚未招募
1 期
Evaluation of ATO-101™ in Patients With Non-Muscle-Invasive Bladder Cancer (PERSEVERANCE EU)Bladder CancerNCT07260162Institut Cancerologie de l'Ouest24
尚未招募
2 期
NANT 2021-02: Randomized MIBG With Vorinostat/Dinutuximab/Vorinostat + DinutuximabNeuroblastomaNCT07261241New Approaches to Neuroblastoma Therapy Consortium118
招募中
3 期
A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma.2025-522860-34-00BeOne Medicines AG196
已完成
2 期
A Phase 2 Trial of BDC-1001 as Single Agent and in Combination with Pertuzumab in Subjects with Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Previously Treated with Trastuzumab Deruxtecan2023-506038-65-00Bolt Biotherapeutics Inc.36
招募中
2 期
Phase 2A/B Efficacy and Safety of Dabogratinib in Participants With Low Grade Upper Tract Urothelial CarcinomaLow Grade Upper Tract Urothelial CarcinomaNCT07265947Tyra Biosciences, Inc230